Chris White is a cancer survivor, patient advocate, and national speaker whose personal journey helped shape one of the most significant milestones in solid tumor cancer treatment. He is the final patient ever dosed in the clinical trial that led to the first FDA approved advanced cellular therapy for any solid tumor cancer in history. This therapy is known as Lifileucel or by its commercial name, AMTAGVI.
Chris is the last of the 153 total patients treated in this groundbreaking study. He is 1 of only 12 participants in the trial with mucosal melanoma and one of just 6 from that group to achieve a clinical response. His outcome is particularly remarkable given that he entered the trial with stage 4 disease, metastasis to major organs and his brain, and no remaining standard treatment options.
On 1/15/2020, Chris received his TIL infusion followed by all 6 recommended doses of IL-2. That was the final treatment he ever required. Within 6 weeks his tumors had reduced by
an estimated 50- 60 %. Within 9 months his scans showed a complete metabolic response. The accelerated approval of AMTAGVI in February 2024 marked a historic shift in cancer care and opened the door for additional biotherapeutics and advanced cellular therapies for solid tumors. Since solid tumors represent roughly 90 percent of all cancer diagnoses and statistics show that about 40 percent of people will face cancer in their lifetime, expanding access to options that preserve both quality and quantity of life is critical. Chris now uses his voice and experience to educate and empower patients, caregivers, clinicians, and researchers. By sharing his story, he provides clarity, perspective, and hope for
everyone navigating cancer or exploring the promise of advanced therapies.